Alkermes, Inc.

This study looks at the long-term safety and how well the drug ALKS 2680 works for people with narcolepsy type 1, type 2, or idiopathic hypersomnia. It is for those who have already finished a related earlier study. Participants will take ALKS 2680 tablets and be monitored for si…

This study tests a new medication, ALKS 2680, to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the drug or a placebo. The main goal is to measure how well they can stay awake during the day after 12 weeks of t…

This study compares a new drug, OLZ/SAM, to the standard medication olanzapine in 220 teens aged 10-17 with schizophrenia or bipolar I disorder. The goal is to see if OLZ/SAM causes less weight gain over 12 weeks and up to a year. Participants must have a reliable family member o…

This study tests a new tablet called ALKS 2680 in 150 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness. Participants will receive either the study drug or a placebo for 12 weeks. The goal is to see if the drug helps people st…

This study tests a new drug, ALKS 2680, to see if it safely reduces excessive daytime sleepiness in people with idiopathic hypersomnia, a condition that causes severe sleepiness without a clear cause. About 96 adults will take either the drug or a placebo daily for 8 weeks. The m…

This study tests an experimental tablet called ALKS 2680 in 150 adults with narcolepsy type 1, a condition causing severe daytime sleepiness and sudden muscle weakness (cataplexy). Participants will receive either the drug or a placebo for 12 weeks. The main goal is to see if the…